category:news
A challenge to Eli Lilly's Tirzepatide patent
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
category:news
drug:eloralinitide
Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects
Ozempic is not likely to directly enlarge the male appendage.
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
category:news
A new risk: Kidney Cancer
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
drug:retatrutide
An update on Retatrutide (May 2025)
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
politics
GLP1s and Tariffs, the story so far
We take a look at the various movements in GLP1 policy by the Trump administration, so far.
drug:wegovy
Wegovy in pill form is coming
Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
drug:nimacimab
Boosting Tirzepatide with Nimacimab
Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly
Eli Lilly suing GLP1 compounders & related companies
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
company:pfizer
Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
category:news
Oral pill Orforglipron delivers stellar results in Phase 3 Trial
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!